{"pmid":32474371,"title":"Rapid implementation and validation of a cold-chain free SARS-CoV-2 diagnostic testing workflow to support surge capacity.","text":["Rapid implementation and validation of a cold-chain free SARS-CoV-2 diagnostic testing workflow to support surge capacity.","BACKGROUND: In January 2020 reports of unidentified severe respiratory illness were described in Wuhan, China. A rapid expansion in cases affecting most countries around the globe led to major changes in the way people live their daily lives. In the United Kingdom, the Department of Health and Social Care directed healthcare providers to establish additional resources to manage the anticipated surge in cases that could overwhelm the health services. A priority area was testing for SARS-CoV-2 RNA and its detection by qualitative RT-PCR. DESIGN: A laboratory workflow twinning research environment with clinical laboratory capabilities was implemented and validated in the University of Birmingham within 4 days of the project initiation. The diagnostic capability was centred on an IVD CE-marked RT-PCR kit and designed to provide surge capacity to the nearby Queen Elizabeth Hospital. The service was initially tasked with testing healthcare workers (HCW) using throat swabs, and subsequently the process investigated the utility of using saliva as an alternative sample type. RESULTS: Between the 8th April 2020 and the 30th April 2020, the laboratory tested a total of 1282 HCW for SARS-CoV-2 RNA in throat swabs. RNA was detected in 54 % of those who reported symptoms compatible with COVID-19, but in only 4% who were asymptomatic. CONCLUSION: This capability was established rapidly and utilised a cold-chain free methodology, applicable to a wide range of settings, and which can provide surge capacity and support to clinical laboratories facing increasing pressure during periods of national crisis.","J Clin Virol","Bosworth, Andrew","Whalley, Celina","Poxon, Charlie","Wanigasooriya, Kasun","Pickles, Oliver","Aldera, Erin L","Papakonstantinou, Danai","Morley, Gabriella L","Walker, Eloise M","Zielinska, Agnieszka E","McLoughlin, Dee","Webster, Craig","Plant, Tim","Ellis, Andrew","Richter, Alex","Kidd, I Michael","Beggs, Andrew D","32474371"],"abstract":["BACKGROUND: In January 2020 reports of unidentified severe respiratory illness were described in Wuhan, China. A rapid expansion in cases affecting most countries around the globe led to major changes in the way people live their daily lives. In the United Kingdom, the Department of Health and Social Care directed healthcare providers to establish additional resources to manage the anticipated surge in cases that could overwhelm the health services. A priority area was testing for SARS-CoV-2 RNA and its detection by qualitative RT-PCR. DESIGN: A laboratory workflow twinning research environment with clinical laboratory capabilities was implemented and validated in the University of Birmingham within 4 days of the project initiation. The diagnostic capability was centred on an IVD CE-marked RT-PCR kit and designed to provide surge capacity to the nearby Queen Elizabeth Hospital. The service was initially tasked with testing healthcare workers (HCW) using throat swabs, and subsequently the process investigated the utility of using saliva as an alternative sample type. RESULTS: Between the 8th April 2020 and the 30th April 2020, the laboratory tested a total of 1282 HCW for SARS-CoV-2 RNA in throat swabs. RNA was detected in 54 % of those who reported symptoms compatible with COVID-19, but in only 4% who were asymptomatic. CONCLUSION: This capability was established rapidly and utilised a cold-chain free methodology, applicable to a wide range of settings, and which can provide surge capacity and support to clinical laboratories facing increasing pressure during periods of national crisis."],"journal":"J Clin Virol","authors":["Bosworth, Andrew","Whalley, Celina","Poxon, Charlie","Wanigasooriya, Kasun","Pickles, Oliver","Aldera, Erin L","Papakonstantinou, Danai","Morley, Gabriella L","Walker, Eloise M","Zielinska, Agnieszka E","McLoughlin, Dee","Webster, Craig","Plant, Tim","Ellis, Andrew","Richter, Alex","Kidd, I Michael","Beggs, Andrew D"],"date":"2020-06-01T11:00:00Z","year":2020,"_id":"32474371","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1016/j.jcv.2020.104469","keywords":["birmingham","covid-19","coronavirus","rapid response","sars-cov-2","viasure qrt-pcr","west midlands"],"locations":["Wuhan","China","United Kingdom"],"countries":["United Kingdom","China"],"countries_codes":["GBR|United Kingdom","CHN|China"],"topics":["Diagnosis"],"weight":1,"_version_":1668341932698370049,"score":9.490897,"similar":[{"pmid":32260471,"title":"In Vitro Diagnostic Assays for COVID-19: Recent Advances and Emerging Trends.","text":["In Vitro Diagnostic Assays for COVID-19: Recent Advances and Emerging Trends.","There have been tremendous advances in in vitro diagnostic (IVD) assays for coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The main IVD assays used for COVID-19 employ real-time reverse transcriptase polymerase chain reaction (RT-PCR) that takes a few hours. But the assay duration has been shortened to 45 min by Cepheid. Of interest is the point-of-care (POC) molecular assay by Abbott that decreased the assay duration to just 5 min. Most molecular tests have been approved by the United States Food and Drug Administration (FDA) under emergency use authorization (EUA) and are Conformite Europeenne (CE) marked. A wide range of serology immunoassays (IAs) have also been developed that complement the molecular assays for the diagnosis of COVID-19. The most prominent IAs are automated chemiluminescent IA (CLIA), manual ELISA, and rapid lateral flow IA (LFIA), which detect the immunoglobulin M (IgM) and immunoglobulin G (IgG) produced in persons in response to SARS-CoV-2 infection. The ongoing research efforts and advances in complementary technologies will pave the way to new POC IVD assays in the coming months. However, the performance of IVD assays needs to be critically evaluated before they are employed for the clinical diagnosis of COVID-19.","Diagnostics (Basel)","Vashist, Sandeep Kumar","32260471"],"abstract":["There have been tremendous advances in in vitro diagnostic (IVD) assays for coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The main IVD assays used for COVID-19 employ real-time reverse transcriptase polymerase chain reaction (RT-PCR) that takes a few hours. But the assay duration has been shortened to 45 min by Cepheid. Of interest is the point-of-care (POC) molecular assay by Abbott that decreased the assay duration to just 5 min. Most molecular tests have been approved by the United States Food and Drug Administration (FDA) under emergency use authorization (EUA) and are Conformite Europeenne (CE) marked. A wide range of serology immunoassays (IAs) have also been developed that complement the molecular assays for the diagnosis of COVID-19. The most prominent IAs are automated chemiluminescent IA (CLIA), manual ELISA, and rapid lateral flow IA (LFIA), which detect the immunoglobulin M (IgM) and immunoglobulin G (IgG) produced in persons in response to SARS-CoV-2 infection. The ongoing research efforts and advances in complementary technologies will pave the way to new POC IVD assays in the coming months. However, the performance of IVD assays needs to be critically evaluated before they are employed for the clinical diagnosis of COVID-19."],"journal":"Diagnostics (Basel)","authors":["Vashist, Sandeep Kumar"],"date":"2020-04-09T11:00:00Z","year":2020,"_id":"32260471","source":"PubMed","week":"202015|Apr 06 - Apr 12","doi":"10.3390/diagnostics10040202","keywords":["covid-19","sars-cov-2","diagnostics","immunoassays","lateral flow immunoassay (lfia)","point-of-care (poc)","real-time reverse transcriptase polymerase chain (rt-pcr)"],"locations":["Abbott"],"topics":["Diagnosis"],"weight":1,"_version_":1666138491909570561,"score":149.02274},{"pmid":32246838,"title":"Hospital surge capacity in a tertiary emergency referral centre during the COVID-19 outbreak in Italy.","text":["Hospital surge capacity in a tertiary emergency referral centre during the COVID-19 outbreak in Italy.","The first person-to-person transmission of the 2019 novel coronavirus in Italy on 21 February 2020 led to an infection chain that represents one of the largest known COVID-19 outbreaks outside Asia. In northern Italy in particular, we rapidly experienced a critical care crisis due to a shortage of intensive care beds, as we expected according to data reported in China. Based on our experience of managing this surge, we produced this review to support other healthcare services in preparedness and training of hospitals during the current coronavirus outbreak. We had a dedicated task force that identified a response plan, which included: (1) establishment of dedicated, cohorted intensive care units for COVID-19-positive patients; (2) design of appropriate procedures for pre-triage, diagnosis and isolation of suspected and confirmed cases; and (3) training of all staff to work in the dedicated intensive care unit, in personal protective equipment usage and patient management. Hospital multidisciplinary and departmental collaboration was needed to work on all principles of surge capacity, including: space definition; supplies provision; staff recruitment; and ad hoc training. Dedicated protocols were applied where full isolation of spaces, staff and patients was implemented. Opening the unit and the whole hospital emergency process required the multidisciplinary, multi-level involvement of healthcare providers and hospital managers all working towards a common goal: patient care and hospital safety. Hospitals should be prepared to face severe disruptions to their routine and it is very likely that protocols and procedures might require re-discussion and updating on a daily basis.","Anaesthesia","Carenzo, L","Costantini, E","Greco, M","Barra, F L","Rendiniello, V","Mainetti, M","Bui, R","Zanella, A","Grasselli, G","Lagioia, M","Protti, A","Cecconi, M","32246838"],"abstract":["The first person-to-person transmission of the 2019 novel coronavirus in Italy on 21 February 2020 led to an infection chain that represents one of the largest known COVID-19 outbreaks outside Asia. In northern Italy in particular, we rapidly experienced a critical care crisis due to a shortage of intensive care beds, as we expected according to data reported in China. Based on our experience of managing this surge, we produced this review to support other healthcare services in preparedness and training of hospitals during the current coronavirus outbreak. We had a dedicated task force that identified a response plan, which included: (1) establishment of dedicated, cohorted intensive care units for COVID-19-positive patients; (2) design of appropriate procedures for pre-triage, diagnosis and isolation of suspected and confirmed cases; and (3) training of all staff to work in the dedicated intensive care unit, in personal protective equipment usage and patient management. Hospital multidisciplinary and departmental collaboration was needed to work on all principles of surge capacity, including: space definition; supplies provision; staff recruitment; and ad hoc training. Dedicated protocols were applied where full isolation of spaces, staff and patients was implemented. Opening the unit and the whole hospital emergency process required the multidisciplinary, multi-level involvement of healthcare providers and hospital managers all working towards a common goal: patient care and hospital safety. Hospitals should be prepared to face severe disruptions to their routine and it is very likely that protocols and procedures might require re-discussion and updating on a daily basis."],"journal":"Anaesthesia","authors":["Carenzo, L","Costantini, E","Greco, M","Barra, F L","Rendiniello, V","Mainetti, M","Bui, R","Zanella, A","Grasselli, G","Lagioia, M","Protti, A","Cecconi, M"],"date":"2020-04-05T11:00:00Z","year":2020,"_id":"32246838","source":"PubMed","week":"202014|Mar 30 - Apr 05","doi":"10.1111/anae.15072","keywords":["covid-19","coronavirus","hospital preparedness","respiratory failure","surge capacity"],"locations":["Italy","Italy","China","Italy"],"countries":["Italy","China"],"countries_codes":["ITA|Italy","CHN|China"],"topics":["Prevention"],"weight":1,"_version_":1666138492034351105,"score":134.58803},{"pmid":32388470,"title":"Rapid and sensitive detection of SARS-CoV-2 RNA using the Simplexa COVID-19 direct assay.","text":["Rapid and sensitive detection of SARS-CoV-2 RNA using the Simplexa COVID-19 direct assay.","BACKGROUND: So far, one of the major drawbacks of the available molecular assays for the diagnosis of severe acute respiratory syndrome Coronavirus-2 (SARS-CoV-2) is the need for viral nucleic acid extraction from clinical specimens. OBJECTIVE: The aim of this study was to evaluate the performances of a newly designed real-time RT-PCR (Simplexa COVID-19 Direct assay), that is established with an all-in-one reagent mix and no separate extraction required. RESULTS: The lower limit of detection (LOD) for both target genes resulted the same: 3.2 (CI: 2.9-3.8) log10 cp/mL and 0.40 (CI: 0.2-1.5) TCID50/mL for S gene while 3.2 log10 (CI: 2.9-3.7) log10 cp/mL and 0.4 (CI: 0.2-1.3) TCID50/mL for ORF1ab. The LOD obtained with extracted viral RNA for both S gene or ORF1ab was 2.7 log10 cp/mL. Crossreactive analysis performed in 20 nasopharyngeal swabs confirmed a 100% of clinical specificity of the assay. Clinical performances of Simplexa COVID-19 Direct assay were assessed in 278 nasopharyngeal swabs tested in parallel with Corman's method. Concordance analysis showed an \"almost perfect\" agreement in SARS-CoV-2 RNA detection between the two assays, being kappa = 0.938; SE = 0.021; 95% CI = 0.896-0.980. CONCLUSIONS: The high sensitivity and specificity of this new assay indicate that it is promising for laboratory diagnosis, enabling highspeed detection in just over one hour, which is significantly faster than the up to five hours currently required by traditional extraction followed by amplification technologies, thus allowing prompt decision making regarding isolation of infected patients.","J Clin Virol","Bordi, Licia","Piralla, Antonio","Lalle, Eleonora","Giardina, Federica","Colavita, Francesca","Tallarita, Monica","Sberna, Giuseppe","Novazzi, Federica","Meschi, Silvia","Castilletti, Concetta","Brisci, Angela","Minnucci, Giulia","Tettamanzi, Veronica","Baldanti, Fausto","Capobianchi, Maria Rosaria","32388470"],"abstract":["BACKGROUND: So far, one of the major drawbacks of the available molecular assays for the diagnosis of severe acute respiratory syndrome Coronavirus-2 (SARS-CoV-2) is the need for viral nucleic acid extraction from clinical specimens. OBJECTIVE: The aim of this study was to evaluate the performances of a newly designed real-time RT-PCR (Simplexa COVID-19 Direct assay), that is established with an all-in-one reagent mix and no separate extraction required. RESULTS: The lower limit of detection (LOD) for both target genes resulted the same: 3.2 (CI: 2.9-3.8) log10 cp/mL and 0.40 (CI: 0.2-1.5) TCID50/mL for S gene while 3.2 log10 (CI: 2.9-3.7) log10 cp/mL and 0.4 (CI: 0.2-1.3) TCID50/mL for ORF1ab. The LOD obtained with extracted viral RNA for both S gene or ORF1ab was 2.7 log10 cp/mL. Crossreactive analysis performed in 20 nasopharyngeal swabs confirmed a 100% of clinical specificity of the assay. Clinical performances of Simplexa COVID-19 Direct assay were assessed in 278 nasopharyngeal swabs tested in parallel with Corman's method. Concordance analysis showed an \"almost perfect\" agreement in SARS-CoV-2 RNA detection between the two assays, being kappa = 0.938; SE = 0.021; 95% CI = 0.896-0.980. CONCLUSIONS: The high sensitivity and specificity of this new assay indicate that it is promising for laboratory diagnosis, enabling highspeed detection in just over one hour, which is significantly faster than the up to five hours currently required by traditional extraction followed by amplification technologies, thus allowing prompt decision making regarding isolation of infected patients."],"journal":"J Clin Virol","authors":["Bordi, Licia","Piralla, Antonio","Lalle, Eleonora","Giardina, Federica","Colavita, Francesca","Tallarita, Monica","Sberna, Giuseppe","Novazzi, Federica","Meschi, Silvia","Castilletti, Concetta","Brisci, Angela","Minnucci, Giulia","Tettamanzi, Veronica","Baldanti, Fausto","Capobianchi, Maria Rosaria"],"date":"2020-05-11T11:00:00Z","year":2020,"_id":"32388470","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.jcv.2020.104416","keywords":["rapid response","real-time rt-pcr","sars-cov-2","surveillance"],"topics":["Diagnosis"],"weight":1,"_version_":1666428892649357312,"score":134.22168},{"pmid":32349032,"title":"Use of Radiographic Features in COVID-19 Diagnosis: Challenges and Perspectives.","text":["Use of Radiographic Features in COVID-19 Diagnosis: Challenges and Perspectives.","The rapid surge and wide-spread of the coronavirus disease-2019 (COVID-19) overshadows the entire medical industries worldwide. The stringent medical resources hinder the diagnostic capacity globally, while 84 thousands of new cases confirmed within a single day of 14 April 2020. Real-time reverse-transcriptase polymerase chain reaction (RT-PCR) with is the current first-line diagnosis, but the false-negative rate remains concerned. Radiographic technologies and tools, including Computed tomography (CT) and Chest X-ray (CXR), were applied for initial screening and follow-up, from which provides detail diagnosis with specific pathologic features for staging and treatment arrangement. Although the radiographic imaging is found less sensitive, numerous CT-positive patients were not screened out by RT-PCR initially and later confirmed as COVID-19 positive. Besides, the shortage of sampling kits and the longer turn-over time of PCR examinations in some areas were noticed due to logistic issues and healthcare burden. In this review, we will discuss the challenges and the future perspectives of using radiographic modalities for COVID-19 diagnosis in view of securing human lives amid the crisis.","J Chin Med Assoc","Chen, Sin-Guang","Chen, Ju-Yu","Yang, Yi-Ping","Chien, Chian-Shiu","Wang, Mong-Lien","Lin, Liang-Ting","32349032"],"abstract":["The rapid surge and wide-spread of the coronavirus disease-2019 (COVID-19) overshadows the entire medical industries worldwide. The stringent medical resources hinder the diagnostic capacity globally, while 84 thousands of new cases confirmed within a single day of 14 April 2020. Real-time reverse-transcriptase polymerase chain reaction (RT-PCR) with is the current first-line diagnosis, but the false-negative rate remains concerned. Radiographic technologies and tools, including Computed tomography (CT) and Chest X-ray (CXR), were applied for initial screening and follow-up, from which provides detail diagnosis with specific pathologic features for staging and treatment arrangement. Although the radiographic imaging is found less sensitive, numerous CT-positive patients were not screened out by RT-PCR initially and later confirmed as COVID-19 positive. Besides, the shortage of sampling kits and the longer turn-over time of PCR examinations in some areas were noticed due to logistic issues and healthcare burden. In this review, we will discuss the challenges and the future perspectives of using radiographic modalities for COVID-19 diagnosis in view of securing human lives amid the crisis."],"journal":"J Chin Med Assoc","authors":["Chen, Sin-Guang","Chen, Ju-Yu","Yang, Yi-Ping","Chien, Chian-Shiu","Wang, Mong-Lien","Lin, Liang-Ting"],"date":"2020-04-30T11:00:00Z","year":2020,"_id":"32349032","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1097/JCMA.0000000000000336","topics":["Diagnosis"],"weight":1,"_version_":1666138495021744129,"score":127.41729},{"pmid":32492760,"title":"Diagnostic Performance of a Rapid Point of Care Test for SARS-CoV-2 in an Urban ED Setting.","text":["Diagnostic Performance of a Rapid Point of Care Test for SARS-CoV-2 in an Urban ED Setting.","The ability to rapidly and accurately identify a patient's COVID-19 status has had significant impact on emergency departments (ED) and health systems globally. Since the identification of SARS-CoV-2 illness in the United States, there has been rapid development in patient testing capacity following initial challenges including sparse availability. This was made possible by increasing availability of diagnostic molecular tests in several formats, from laboratory based traditional, RT-PCR methods to near patient testing rapid point of care PCR tests.","Acad Emerg Med","McDonald, Samuel","Courtney, D Mark","Clark, Andrew E","Muthukumar, Alagarraju","Lee, Francesca","Balani, Jyoti","Mahimainathan, Lenin","Bararia, Anjali","Oliver, Dwight","Sarode, Ravi","Diercks, Deborah","32492760"],"abstract":["The ability to rapidly and accurately identify a patient's COVID-19 status has had significant impact on emergency departments (ED) and health systems globally. Since the identification of SARS-CoV-2 illness in the United States, there has been rapid development in patient testing capacity following initial challenges including sparse availability. This was made possible by increasing availability of diagnostic molecular tests in several formats, from laboratory based traditional, RT-PCR methods to near patient testing rapid point of care PCR tests."],"journal":"Acad Emerg Med","authors":["McDonald, Samuel","Courtney, D Mark","Clark, Andrew E","Muthukumar, Alagarraju","Lee, Francesca","Balani, Jyoti","Mahimainathan, Lenin","Bararia, Anjali","Oliver, Dwight","Sarode, Ravi","Diercks, Deborah"],"date":"2020-06-04T11:00:00Z","year":2020,"_id":"32492760","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1111/acem.14039","keywords":["covid-19","emergency care","point of care testing","sars-cov-2"],"locations":["United States"],"countries":["United States"],"countries_codes":["USA|United States"],"topics":["Diagnosis"],"weight":1,"_version_":1668892169308471296,"score":127.27998}]}